Probi AB (publ) (OTCPK: PBBI.F)
Health Care · Biotechnology · SE
$—
— today · — 1Y
Probi AB (publ) (OTCPK: PBBI.F) operates in the Biotechnology industry within the Health Care sector.
Tweenvest scores Probi AB (publ) across four factors: quality 68/100, growth 0/100, dividend 91/100. Its strongest factor is dividend.
PBBI.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $62.15M
- P/E
- —
- EPS
- 0.96
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 157
- Next earnings
- —
About Probi AB (publ)
Probi AB (publ) researches, develops, manufactures, markets, and sells probiotics for health, pharmaceutical, and food companies. The company conducts research primarily in the fields of gastrointestinal health, digestive health, immune health, bone health, and iron absorption, as well as children's, women's, and senior health. It provides dietary supplement, and food and beverage products in the form of capsules, tablets and spheres, chewable tablets, powder, fruit drinks, shots, carbonated beverages, and recovery drinks. The company sells its products approximately in 40 countries worldwide. It has a collaboration with Örebro University for research into exploration needle free vaccines; and a collaboration with La Trobe University to conduct a clinical trial to investigate the effect of Probi Osteo in an Australian women. The company was incorporated in 1991 and is headquartered in Lund, Sweden. Probi AB (publ) is a subsidiary of Symrise AG.
- ISIN
- SE0001280355
- Founded
- 1991
- Listed since
- Dec 2, 2004
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.50 | -0.55% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.55 | +0.28% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $144.90 | -0.83% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $548.37 | +0.06% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $823.94 | -1.21% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $135.64 | -6.50% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.